Related Experiment Video
Updated: Jun 13, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Subtle variations in Pten dose determine cancer susceptibility
Andrea Alimonti1, Arkaitz Carracedo, John G Clohessy
1Cancer Genetics Program, Department of Medicine, Beth Israel Deaconess Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Subtle reductions in tumor suppressor gene (TSG) dosage, like Pten, can promote cancer. This study demonstrates that even with Pten levels above heterozygosity, mammary tissues showed altered biology and gene expression, leading to tumor development.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Cancer susceptibility is linked to genetic alterations in tumor suppressor genes (TSGs).
- Hypotheses suggest subtle TSG expression variations can drive cancer, but in vivo evidence is limited.
- PTEN (Phosphatase and tensin homolog) is a critical TSG frequently altered in human cancers and inherited cancer syndromes.
Purpose of the Study:
- To investigate the in vivo impact of subtle reductions in TSG expression on cancer development.
- To explore the role of PTEN dosage in tumorigenesis, particularly in breast cancer.
- To present an alternative model for cancer initiation based on reduced TSG dose.
Main Methods:
- Analysis of Pten hypermorphic mice (Pten(hy/+)) expressing 80% of normal Pten levels.
- Characterization of tumor spectrum and penetrance in Pten(hy/+) mice, focusing on breast tumors.
- Examination of Pten levels and gene expression profiles in mammary tissues and tumors.
Main Results:
- Pten(hy/+) mice developed a range of tumors, with high penetrance of breast tumors.
- All analyzed breast tumors retained two intact Pten copies and Pten levels above heterozygosity.
- Subtle Pten downregulation altered mammary tissue biology and expression of proliferation-related genes.
Conclusions:
- Reduced PTEN dosage, even above heterozygous levels, can predispose to tissue-specific tumorigenesis.
- This study supports a model where subtle TSG dose reductions contribute to cancer development.
- Altered gene expression profiles in response to reduced PTEN highlight pathways involved in cancer progression.
Related Concept Videos
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Principles of Pharmacogenetics: Types of Genetic Variants
Abnormal Proliferation
